Magnesium-L-Threonate Improves Menopausal Symptoms
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age40-60
SponsorGuangdong Provincial People's Hospital
About this trial
This trial has a randomized, single-blind, single-center, parallel-controlled design, with participant screening and trial implementation conducted at Guangdong Provincial People's Hospital. The study evaluate the efficacy of oral magnesium L-threonate supplementation on improving menopausal symptoms and quality of life among peri/post-menopausal women.
This trial aims to explore whether oral magnesium L-threonate supplementation could alleviate menopausal syndromes.
Participants will randomly assigned to conduct oral magnesium L-threonate supplementation or placebo for 8 weeks. Face-to-face and internet follow up will be conducted once per 2 weeks.
Eligibility criteria
Qualifiers
Women aged 40-60 years;
Postmenopausal status or in the late menopausal transition stage. 3. Postmenopausal status is defined as: natural menopause with no menstruation in the past 12 months. The late menopausal transition stage will be defined as: amenorrhea for at least 60 days within the past 12 months;
Disqualifiers
History of bilateral oophorectomy or hysterectomy;
Current or past use of magnesium L-threonate preparations or similar nutrient formulations within the last 3 months;
Definite history of gastrointestinal diseases that may affect the absorption of the investigational drug;
Definite history of liver diseases that may affect the metabolism of the investigational drug;
Trial design
Treatments tested in this trial
- Magnesium-L-Threonate
- Placebo
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov